Biosynth, a supplier of essential raw materials and services for the life sciences and diagnostics sectors, has opened an expanded good manufacturing practice (GMP) bioconjugation facility at its Berlin site in Germany.
Salipro Biotech has announced a research collaboration with Daewoong Pharmaceutical, focusing on the development of new small molecule drugs.
PCI Pharma Services (PCI) has concluded the acquisition of Ajinomoto Althea, a sterile fill-finish contract development and manufacturing organisation (CDMO) based in the US.
Clinical-stage company Parvus Therapeutics has expanded its collaboration with biomanufacturing company National Resilience to develop and manufacture the autoimmune drug candidate, PVT401, for inflammatory bowel disease (IBD).
Ring Therapeutics has entered into new strategic partnerships with the Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI) to enhance research and development (R&D) efforts in the biomedical sciences sector.
Machine learning-enabled drug discovery and development company insitro has executed three agreements with Lilly to advance new treatments for metabolic diseases.
Preclinical contract research organisation (CRO) PsychoGenics has received an award from the US National Institutes of Health (NIH) to conduct the testing and identification of new investigational therapeutics aimed at treating pain.
AstraZeneca has signed an exclusive agreement to license CSPC Pharmaceutical’s new lipid-lowering therapy, YS2302018, for treating patients with dyslipidaemia.
The US Food and Drug Administration (FDA) has granted fast track designation for Elevation Oncology’s EO-3021, a treatment for patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer.
ENCell has entered into a strategic alliance and licencing agreement with Lucy Biotech for EN001, a next-generation mesenchymal stem cell therapy.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.